Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus ROLVEDON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus ROLVEDON.
CHLORZOXAZONE vs ROLVEDON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
ROLVEDON (eflapegrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) agonist. It binds to G-CSF receptors on neutrophil progenitors, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
5 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
Approximately 20 hours in adults; prolonged in renal impairment, requiring dose adjustment
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily renal; approximately 80% of the dose excreted unchanged in urine, with minor biliary/fecal elimination (<10%)
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."